The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTreatt Regulatory News (TET)

Share Price Information for Treatt (TET)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 486.00
Bid: 485.50
Ask: 489.00
Change: 0.00 (0.00%)
Spread: 3.50 (0.721%)
Open: 480.00
High: 489.50
Low: 480.00
Prev. Close: 486.00
TET Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

22 Jan 2021 07:00

RNS Number : 5318M
Treatt PLC
22 January 2021
 

22 January 2021

TREATT PLC

("Treatt" or "the Group")

Trading update

Strong trading - profits expected to materially exceed market consensus

Treatt, the manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the beverage, flavour and fragrance industries, today updates on trading since the start of its financial year ending 30 September 2021 ("FY21").

Highlights

· Strong operating performance across multiple categories and customers, with new organic revenue growth and enhanced margins from improving product mix.

· Profits for the first four months of the current financial year are expected to be ahead of Board's previous expectations for the period.

· Continued partnering with customers to develop exciting products in the fast-evolving beverages market is driving potential for further revenue and margin growth.

· Headwinds from COVID-19, the geopolitical landscape and commodity/currency risks remain.

· Overall, the Board is cautiously optimistic that the current strong momentum will result in profit before tax and exceptional items for FY21 materially exceeding the current market consensus* of £15.1m.

Trading performance

As reported in our FY20 results announcement on 24 November 2020, the Group had a strong start to the new financial year, and this has continued with the trading performance in the year to date being significantly better than expected.

The Group is performing particularly well in its citrus, health & wellness, fruit & vegetables and tea categories. Some material new business wins have been achieved including in the global alcoholic seltzer category which is continuing to grow strongly. Treatt is well positioned as a supplier of natural extracts including its sugar reduction solutions; the Group's technical expertise enables it to add significant value to customers across a growing range of applications resulting in margin expansion as well as revenue growth.

Whilst some parts of our product portfolio continue to be impacted from subdued on-trade demand due to the closure of venues in many parts of the World, this has been more than offset by increased demand from off-trade channels.

The Board considers that the strong trading momentum shown in these first few months of the current financial year will continue into H2 but is mindful that the Group faces the same uncertainties as our customers regarding the ongoing COVID-19 global pandemic, potential further lockdowns in our key markets and the volatile geopolitical landscape, with potential impacts on demand, FX rates and commodity prices. Nevertheless, the better than expected performance for the first four months of the year and the level of the order book leads the Board to be cautiously optimistic about continued growth in revenues, margins and profits for the rest of FY21, with profit before tax and exceptional items for FY21 expected to materially exceed current consensus* of £15.1m.

Daemmon Reeve, CEO, commented:

"We're encouraged by our strong trading momentum continuing into the current financial year. Performance has been positive across a number of our key categories, with particular growth in our solutions for the expanding alcoholic seltzer market, utilising our expertise in natural extracts.

"Whilst mindful of the global backdrop, we are confident that we can make further progress this year, to grow organic revenue across an increasingly global and diversified customer base who benefit from our technical expertise and value-add approach."

 

* Treatt compiled consensus of analyst forecasts for FY21 of profit before tax and exceptional items.

 

Treatt plc +44 (0)1284 702500

Daemmon Reeve Chief Executive Officer

Richard Hope Chief Financial Officer

 

Broker

Investec Bank Plc +44 (0)20 7597 5970

Patrick Robb

David Anderson

Alex Wright

 

Financial PR

MHP Communications +44 (0) 20 3128 8789

Tim Rowntree

Simon Hockridge

Catherine Chapman

 

About the Group

Treatt is a global, independent manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the flavour, fragrance and multinational consumer product industries, particularly in the beverage sector. Renowned for its technical expertise and knowledge of ingredients, their origins and market conditions, Treatt is recognised as a leader in its field.

 

The Group employs over 300 staff in Europe, North America and Asia and has manufacturing facilities in the UK and US. Its international footprint enables the Group to deliver powerful and integrated solutions for the food, beverage and fragrance industries across the globe.

 

 

For further information about the Group, visit www.treatt.com.

 

Information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements that are subject to risk factors associated with, among other things, the economic and business circumstances occurring from time to time in the countries, sectors and markets in which the Group operates. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a wide range of variables which could cause actual results to differ materially from those currently anticipated. No assurances can be given that the forward-looking statements in this announcement will be realised. The forward-looking statements reflect the knowledge and information available at the date of preparation of this announcement and the Group undertakes no obligation to update these forward-looking statements. Nothing in this announcement should be construed as a profit forecast.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLALLILFIL
Date   Source Headline
10th Apr 20247:00 amRNSHalf Year Trading Update & Notice of Results
19th Mar 20243:40 pmRNSNotification of Transactions of Directors
4th Mar 20247:00 amRNSAppointment of Chief Executive Officer
13th Feb 20249:35 amRNSHolding(s) in Company
31st Jan 20242:41 pmRNSNotification of Transaction of PDMR
25th Jan 20243:49 pmRNSResult of AGM
25th Jan 20247:00 amRNSAGM Trading Update
23rd Jan 20241:57 pmRNSTotal Voting Rights
21st Dec 20232:07 pmRNSNotification of Transaction of Director
15th Dec 20236:09 pmRNSNotification of Transactions - Replacement
15th Dec 20234:42 pmRNSNotification of Transactions of Directors
13th Dec 20237:00 amRNSInterim Chief Financial Officer Appointment
12th Dec 20234:24 pmRNSAnnual Report and Notice of Annual General Meeting
1st Dec 20237:01 amRNSBlock Listing Six Monthly Return
1st Dec 20237:00 amRNSBlock Listing Six Monthly Return
28th Nov 20234:15 pmRNS2023 Final Dividend
28th Nov 20237:00 amRNSFull Year Results
20th Oct 20237:00 amRNSCEO Succession
10th Oct 20237:00 amRNSTrading Update
18th Sep 20234:11 pmRNSHolding(s) in Company
15th Aug 20234:14 pmRNSNotification of Transactions of Directors
28th Jul 202310:43 amRNSTotal Voting Rights
13th Jul 202312:15 pmRNSReplacement - Director/PDMR Shareholding
13th Jul 202311:09 amRNSNotification of Transaction of Director
21st Jun 20234:05 pmRNSNotification of Transactions of Director
12th Jun 20234:13 pmRNSDirector Declaration
7th Jun 20232:28 pmRNSBlock Listing Application
1st Jun 20237:00 amRNSBlock listing Six Monthly Return
19th May 20235:10 pmRNSHolding(s) in Company
19th May 20234:28 pmRNSHolding(s) in Company
9th May 20237:00 amRNSHalf Year Results
12th Apr 20237:00 amRNSHalf Year Trading Update and Notice of Results
20th Mar 20233:28 pmRNSNotification of Transactions of Directors
7th Mar 20233:25 pmRNSDirector/PDMR Shareholding
22nd Feb 20233:06 pmRNSHolding(s) in Company
21st Feb 202312:51 pmRNSNotification of Transactions of Director
21st Feb 202312:49 pmRNSNotification of Transactions of Director
20th Feb 202311:01 amRNSNotification of Transaction of a Director
30th Jan 20231:49 pmRNSHolding(s) in Company
27th Jan 20233:10 pmRNSResult of AGM
27th Jan 20237:00 amRNSAGM Trading Update
10th Jan 20235:05 pmRNSVoting Rights and Capital
28th Dec 20227:00 amRNSNotification of Transaction of Director
28th Dec 20227:00 amRNSAnnual Report and Notice of Annual General Meeting
20th Dec 202212:20 pmRNSBoard Appointment and Board Committee Changes
16th Dec 20221:25 pmRNSNotification of Transactions of Directors
1st Dec 20223:55 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st Dec 20223:55 pmRNSBLOCK LISTING SIX MONTHLY RETURN
29th Nov 20224:36 pmRNSPrice Monitoring Extension
29th Nov 20227:10 amRNSFull Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.